These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36515721)

  • 1. [Risankizumab in patients with Crohn's disease].
    Blumenstein I; Nitschmann S
    Inn Med (Heidelb); 2023 Jan; 64(1):102-106. PubMed ID: 36515721
    [No Abstract]   [Full Text] [Related]  

  • 2. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab (Skyrizi) - An IL-23 antagonist for Crohn's disease.
    Med Lett Drugs Ther; 2022 Dec; 64(1666):153-157. PubMed ID: 36542348
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab for Crohn's disease.
    Hibi T
    Lancet; 2022 May; 399(10340):1992-1993. PubMed ID: 35644143
    [No Abstract]   [Full Text] [Related]  

  • 6. Risankizumab: First Global Approval.
    McKeage K; Duggan S
    Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
    Tursi A; Florio T; Tiano M
    Eur J Gastroenterol Hepatol; 2021 Nov; 33(11):1462-1464. PubMed ID: 34597287
    [No Abstract]   [Full Text] [Related]  

  • 8. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract]